Coya Therapeutics Inc [COYA] stock prices are down -1.62% to $6.07 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The COYA shares have gain 5.93% over the last week, with a monthly amount drifted -0.82%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Coya Therapeutics Inc [NASDAQ: COYA] stock has seen the most recent analyst activity on December 04, 2024, when D. Boral Capital initiated its Buy rating and assigned the stock a price target of $15.
The stock price of Coya Therapeutics Inc [COYA] has been fluctuating between $4.75 and $10.69 over the past year. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Coya Therapeutics Inc [NASDAQ: COYA] shares were valued at $6.07 at the most recent close of the market. An investor can expect a potential return of 196.54% based on the average COYA price forecast.
Analyzing the COYA fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -1.17%, Pretax Profit Margin comes in at -1.04%, and Net Profit Margin reading is -1.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.32 and Total Capital is -0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.94 points at the first support level, and at 5.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.29, and for the 2nd resistance point, it is at 6.50.
Ratios To Look Out For
It’s worth pointing out that Coya Therapeutics Inc [NASDAQ:COYA]’s Current Ratio is 15.31. As well, the Quick Ratio is 15.31, while the Cash Ratio is 13.39. Considering the valuation of this stock, the price to sales ratio is 10.62, the price to book ratio is 2.89.
Transactions by insiders
Recent insider trading involved SNYDER DAVID S, Chief Financial Officer, that happened on Nov 14 ’24 when 1800.0 shares were purchased. Chief Executive Officer, Swaminathan Arun completed a deal on Nov 13 ’24 to buy 5000.0 shares. Meanwhile, Chief Medical Officer Grossman Fred bought 2710.0 shares on Nov 11 ’24.
